Sensei Biotherapeutics Adds Oncology Expert to Board
Ticker: SNSE · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Sensei Bio adds oncology expert Dr. Jonathan Jonathan to its board.
AI Summary
Sensei Biotherapeutics, Inc. announced on June 26, 2024, the election of Dr. Jonathan Jonathan as a new Class II director to its Board of Directors. Dr. Jonathan brings extensive experience in oncology drug development and commercialization. This appointment is part of the company's ongoing efforts to strengthen its leadership team as it advances its pipeline.
Why It Matters
The addition of an experienced oncology drug developer to the board could signal a strategic focus on advancing their cancer therapies and potentially attract further investment.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low risk.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- Dr. Jonathan Jonathan (person) — Newly elected Class II director
- June 26, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. Jonathan Jonathan and what is his background?
Dr. Jonathan Jonathan is a newly elected Class II director with extensive experience in oncology drug development and commercialization.
When was Dr. Jonathan Jonathan elected to the board?
Dr. Jonathan Jonathan was elected to the board on June 26, 2024.
What class of director is Dr. Jonathan Jonathan?
Dr. Jonathan Jonathan is a Class II director.
What is the primary business of Sensei Biotherapeutics, Inc.?
Sensei Biotherapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the principal executive office address for Sensei Biotherapeutics, Inc.?
The principal executive offices are located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2024-06-27 17:01:04
Filing Documents
- d117545d8k.htm (8-K) — 24KB
- 0001193125-24-170690.txt ( ) — 182KB
- snse-20240626.xsd (EX-101.SCH) — 4KB
- snse-20240626_def.xml (EX-101.DEF) — 14KB
- snse-20240626_lab.xml (EX-101.LAB) — 23KB
- snse-20240626_pre.xml (EX-101.PRE) — 15KB
- d117545d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: June 27, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3